There is a desperate need for rapid turnaround of transplant clinical trials to bring forward breakthrough therapies. IMPACT is a new partnership that aims to improve regulation and transplant outcomes. Speaking here, Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, from University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, introduces key trials that will be starting soon, including the PRO-DLI trial (NCT02856464), a trial investigating CPX-351 for untreated acute myeloid leukemia (NCT03335267). This video was recorded at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal.
The IMPACT Partnership: Improving regulation and turnaround of transplant clinical trials
